iBio Announces Private Placement to Fund Pipeline Expansion
TipRanks (Mon, 12-Jan 5:56 PM ET)
iBio announces private placement financing to raise ~$26M
Seeking Alpha News (Fri, 9-Jan 7:54 AM ET)
iBio Announces $26 Million Private Placement
Globe Newswire (Fri, 9-Jan 7:00 AM ET)
iBio to Participate in the 8th Annual Evercore Healthcare Conference
Globe Newswire (Mon, 24-Nov 4:15 PM ET)
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 12-Nov 4:01 PM ET)
Globe Newswire (Thu, 30-Oct 7:00 AM ET)
iBio’s Spotlight at Guggenheim Healthcare Conference Highlights Strategic Push in Obesity Innovation
Market Chameleon (Thu, 23-Oct 6:34 AM ET)
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Globe Newswire (Thu, 23-Oct 7:00 AM ET)
iBio Showcases Promising Activin E Antibody Data Ahead of Obesity and Cardiometabolic Conferences
Market Chameleon (Wed, 22-Oct 7:09 AM ET)
Market Chameleon (Tue, 21-Oct 6:28 AM ET)
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Ibio trades on the NASDAQ stock market under the symbol IBIO.
As of January 12, 2026, IBIO stock price was flat at $2.70 with 3,261,370 million shares trading.
IBIO has a beta of 0.34, meaning it tends to be less sensitive to market movements. IBIO has a correlation of 0.00 to the broad based SPY ETF.
IBIO has a market cap of $60.72 million. This is considered a Micro Cap stock.
Last quarter Ibio reported $100,000 in Revenue and -$.11 earnings per share. This beat revenue expectation by $45,000 and missed earnings estimates by -$.04.
In the last 3 years, IBIO traded as high as $52.00 and as low as $.56.
The top ETF exchange traded funds that IBIO belongs to (by Net Assets): VTI, VXF.
IBIO has underperformed the market in the last year with a return of -0.7%, while SPY returned +19.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in IBIO shares. However, IBIO has outperformed the market in the last 3 month and 2 week periods, returning +216.2% and +42.9%, while SPY returned +3.9% and +0.7%, respectively. This indicates IBIO has been having a stronger performance recently.
IBIO support price is $2.43 and resistance is $2.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBIO shares will trade within this expected range on the day.
